Lurbinectedin is a drug that has been approved by the FDA for the treatment of metastatic small cell lung cancer. It has not been approved for all types of cancer [3]. Lurbinectedin is a type of chemotherapy drug that works by preventing cancer cells from dividing and growing [2]. It is administered intravenously by a healthcare professional [2]. Lurbinectedin was granted accelerated approval by the FDA in June 2020 based on the results of a clinical trial that showed it to be effective in treating metastatic small cell lung cancer [3]. It is important to note that the approval of lurbinectedin for small cell lung cancer does not mean that it is effective for other types of cancer [1]. Patients should consult with their healthcare provider to determine the best course of treatment for their specific type of cancer.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.cancer.gov/about-cancer/treatment/drugs/lurbinectedin
[3] https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-lurbinectedin-metastatic-small-cell-lung-cancer